Edition:
United States

T2 Biosystems Inc (TTOO.OQ)

TTOO.OQ on NASDAQ Stock Exchange Global Market

4.15USD
15 Dec 2017
Change (% chg)

$-0.11 (-2.58%)
Prev Close
$4.26
Open
$4.25
Day's High
$4.38
Day's Low
$4.13
Volume
44,157
Avg. Vol
59,399
52-wk High
$6.97
52-wk Low
$2.51

Latest Key Developments (Source: Significant Developments)

T2 Biosystems Q3 loss per share $0.45
Thursday, 2 Nov 2017 04:05pm EDT 

Nov 2 (Reuters) - T2 Biosystems Inc :T2 biosystems reports third quarter 2017 financial results and provides company update.Q3 loss per share $0.45.Sees q4 revenue $1.1 million to $1.3 million.Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S.Q3 revenue $1.1 million versus i/b/e/s view $1.1 million.T2 biosystems inc - ‍company reaffirms expectations regarding timeframe for fda clearance of t2bacteria panel​.T2 biosystems inc - ‍continues to prepare for commercial launch of t2bacteria panel in u.s. As early as year-end, pending market clearance by fda.​.T2 biosystems inc - ‍cash and cash equivalents as of sept 30 with additional remaining liquidity on term loan , should extend cash runway into h1 2019​.  Full Article

T2 Biosystems announces pricing of public offering of common stock
Friday, 15 Sep 2017 08:20am EDT 

Sept 15 (Reuters) - T2 Biosystems Inc :T2 Biosystems announces pricing of public offering of common stock.Says public offering of 4.38 million common shares priced at $4 per share.  Full Article

T2 Biosystems announces proposed public offering of common stock
Thursday, 14 Sep 2017 04:11pm EDT 

Sept 15 (Reuters) - T2 Biosystems Inc :T2 Biosystems announces proposed public offering of common stock.  Full Article

T2 Biosystems submits 510(K) application to the FDA for review of T2Bacteria Panel
Monday, 11 Sep 2017 08:00am EDT 

Sept 11 (Reuters) - T2 Biosystems Inc :T2 Biosystems submits 510(K) application to the FDA for review of T2Bacteria Panel‍​.  Full Article

T2 Biosystems, Cidara Therapeutics enter partnership for commercial placement of T2Dx instruments
Wednesday, 6 Sep 2017 11:05am EDT 

Sept 6 (Reuters) - T2 Biosystems::Co, Cidara Therapeutics entered into exclusive partnership for commercial placement of T2Dx instruments to support CD101 drug trials​.Program is designed to accelerate enrollment in Cidara's CD101 trials and to increase uptake of T2's products..  Full Article

T2 Biosystems to collaborate with CDC to detect emerging superbug Candida Auris​
Wednesday, 6 Sep 2017 07:00am EDT 

Sept 6 (Reuters) - T2 Biosystems Inc :T2 Biosystems Inc - ‍announces collaboration with CDC to detect emerging superbug Candida Auris​.  Full Article

T2 Biosystems entered into amendment to supply agreement as of Oct 10, 2014
Tuesday, 5 Sep 2017 03:44pm EDT 

Sept 5 (Reuters) - T2 Biosystems Inc ::On August 29, Co & Smc Ltd entered into amendment to supply agreement amending certain supply agreement, dated as of Oct 10, 2014.Says ‍amendment extends term of supply agreement from October 10, 2017 to December 31, 2017 - SEC filing​.  Full Article

T2 Biosystems Q2 loss per share $0.50
Thursday, 3 Aug 2017 04:05pm EDT 

Aug 3 (Reuters) - T2 Biosystems Inc :T2 Biosystems reports second quarter 2017 financial results; provides company update.Q2 loss per share $0.50.Q2 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S.T2 Biosystems Inc - ‍Q2 product revenue was $735,000, a $584,000 increase from Q2 of 2016​.T2 Biosystems Inc - ‍product revenue growth of at least 20% sequentially is projected in Q3 of 2017​.  Full Article

T2 biosystems gets CE mark for its T2bacteria panel
Tuesday, 18 Jul 2017 08:00am EDT 

July 18 (Reuters) - T2 Biosystems Inc ::T2 Biosystems Inc says ‍has received a CE mark for its T2bacteria panel, allowing for sale and distribution of product within European Union​.  Full Article

Tiger Management reports 5.68 pct passive stake in T2 Biosystems
Monday, 5 Jun 2017 05:26pm EDT 

June 5 (Reuters) - T2 Biosystems Inc ::Tiger Management Llc reports 5.68 percent passive stake in T2 biosystems Inc as of may 25 - sec filing.  Full Article

BRIEF-T2 Biosystems Q3 loss per share $0.45

* T2 biosystems reports third quarter 2017 financial results and provides company update